NexImmune is a rapidly growing leader in the emerging field of antigen-directed immunotherapies. We are developing a novel technology that uses natural biology to orchestrate a targeted cell-mediated immune response across a broad range of diseases. We can customize our technology to “intensify” a targeted immune response to treat cancer or infectious disease. Conversely, we can also customize it to “dampen” an overactive immune response to treat autoimmune disorders.

Latest News

AUGUST 31, 2023

NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy

Read More >

AUGUST 10, 2023

NexImmune Reports Second Quarter 2023 Financial Results and Provides Business Updates

Read More >

JUNE 05, 2023

NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting

Read More >

T cells are the “foot soldiers” of the immune system.

Their role is to identify, engage, and destroy diseased cells within our bodies. Each T cell requires a specific set of instructions, otherwise the T cell is incapable of performing its critical immune function. These instructions are provided through very specific signaling proteins and are normally delivered to the T cell by dendritic cells. In many diseases, the dendritic cell becomes dysfunctional and is no longer able to direct healthy T cell function, and ultimately the immune system breaks down.

NexImmune “AIMs” to orchestrate cell-mediated immune responses across a range of diseases.

With an urgent drive and singular focus on meeting the needs of waiting patients, our team is executing a bold strategy to deliver immunotherapies that go beyond incremental improvements to those with curative potential.

The foundation of our unique approach focuses on modulating the role that T cells play within the immune system. Our proprietary nanotechnology platform, Artificial Immune Modulation (AIM), employs natural biology to direct specific T cell-mediated immune responses capable of treating a variety of diseases.

The AIM nanoparticles use biology similar to that of healthy dendritic cells to deliver the instructions necessary to direct healthy T cell function. Each AIM nanoparticle can be programmed to deliver customized instructions directly to specific populations of T cells, bringing pharmaceutical precision to cell therapy.